Immune checkpoint blockade therapy for cancer: An overview of FDA-approved immune checkpoint inhibitors

Dighe, 1994, Enhanced in vivo growth and resistance to rejection of tumor cells expressing dominant negative IFN gamma receptors, Immunity, 1, 447, 10.1016/1074-7613(94)90087-6

Levitsky, 1994, In vivo priming of two distinct antitumor effector populations: the role of MHC class I expression, J. Exp. Med., 179, 1215, 10.1084/jem.179.4.1215

van den Broek, 1996, Decreased tumor surveillance in perforin-deficient mice, J. Exp. Med., 184, 1781, 10.1084/jem.184.5.1781

Kaplan, 1998, Demonstration of an interferon gamma-dependent tumor surveillance system in immunocompetent mice, Proc. Natl. Acad. Sci. U. S. A., 95, 7556, 10.1073/pnas.95.13.7556

Hung, 1998, The central role of CD4(+) T cells in the antitumor immune response, J. Exp. Med., 188, 2357, 10.1084/jem.188.12.2357

Smyth, 2000, Perforin-mediated cytotoxicity is critical for surveillance of spontaneous lymphoma, J. Exp. Med., 192, 755, 10.1084/jem.192.5.755

Shankaran, 2001, IFNgamma and lymphocytes prevent primary tumour development and shape tumour immunogenicity, Nature, 410, 1107, 10.1038/35074122

Smith, 1965, Spontaneous regression of primary malignant melanomas with regional metastases, Cancer, 18, 1399, 10.1002/1097-0142(196511)18:11<1399::AID-CNCR2820181104>3.0.CO;2-R

Saleh, 2001, Primary melanoma tumour regression associated with an immune response to the tumour-associated antigen melan-A/MART-1, Int. J. Cancer, 94, 551, 10.1002/ijc.1491

Deng, 2010, Accumulation of foxp3+ T regulatory cells in draining lymph nodes correlates with disease progression and immune suppression in colorectal cancer patients, Clin. Cancer Res., 16, 4105, 10.1158/1078-0432.CCR-10-1073

Severson, 2015, PD-1+Tim-3+ CD8+ T lymphocytes display varied degrees of functional exhaustion in patients with regionally metastatic differentiated thyroid cancer, Cancer Immunol. Res., 3, 620, 10.1158/2326-6066.CIR-14-0201

Shahinian, 1993, Differential T cell costimulatory requirements in CD28-deficient mice, Science, 261, 609, 10.1126/science.7688139

Joffre, 2009, Inflammatory signals in dendritic cell activation and the induction of adaptive immunity, Immunol. Rev., 227, 234, 10.1111/j.1600-065X.2008.00718.x

Chen, 2013, Molecular mechanisms of T cell co-stimulation and co-inhibition, Nat. Rev. Immunol., 13, 227, 10.1038/nri3405

Walunas, 1994, CTLA-4 can function as a negative regulator of T cell activation, Immunity, 1, 405, 10.1016/1074-7613(94)90071-X

Qureshi, 2011, Trans-endocytosis of CD80 and CD86: a molecular basis for the cell-extrinsic function of CTLA-4, Science, 332, 600, 10.1126/science.1202947

Krummel, 1995, CD28 and CTLA-4 have opposing effects on the response of T cells to stimulation, J. Exp. Med., 182, 459, 10.1084/jem.182.2.459

Greenwald, 2001, CTLA-4 regulates induction of anergy in vivo, Immunity, 14, 145, 10.1016/S1074-7613(01)00097-8

Krummel, 1996, CTLA-4 engagement inhibits IL-2 accumulation and cell cycle progression upon activation of resting T cells, J. Exp. Med., 183, 2533, 10.1084/jem.183.6.2533

Chambers, 1998, Secondary but not primary T cell responses are enhanced in CTLA-4-deficient CD8+ T cells, Eur. J. Immunol., 28, 3137, 10.1002/(SICI)1521-4141(199810)28:10<3137::AID-IMMU3137>3.0.CO;2-X

Wing, 2008, CTLA-4 control over Foxp3+ regulatory T cell function, Science, 322, 271, 10.1126/science.1160062

Peggs, 2009, Blockade of CTLA-4 on both effector and regulatory T cell compartments contributes to the antitumor activity of anti–CTLA-4 antibodies, J. Exp. Med., 206, 1717, 10.1084/jem.20082492

Wei, 2017, Distinct cellular mechanisms underlie anti-CTLA-4 and anti-PD-1 checkpoint blockade, Cell, 170, 1120, 10.1016/j.cell.2017.07.024

Hodi, 2010, Improved survival with ipilimumab in patients with metastatic melanoma, N. Engl. J. Med., 363, 711, 10.1056/NEJMoa1003466

Schadendorf, 2015, Pooled analysis of long-term survival data from phase II and phase III trials of ipilimumab in unresectable or metastatic melanoma, J. Clin. Oncol., 33, 1889, 10.1200/JCO.2014.56.2736

Robert, 2011, Ipilimumab plus dacarbazine for previously untreated metastatic melanoma, N. Engl. J. Med., 364, 2517, 10.1056/NEJMoa1104621

Nishimura, 1999, Development of lupus-like autoimmune diseases by disruption of the PD-1 gene encoding an ITIM motif-carrying immunoreceptor, Immunity, 11, 141, 10.1016/S1074-7613(00)80089-8

Freeman, 2000, Engagement of the PD-1 immunoinhibitory receptor by a novel B7 family member leads to negative regulation of lymphocyte activation, J. Exp. Med., 192, 1027, 10.1084/jem.192.7.1027

Latchman, 2001, PD-L2 is a second ligand for PD-1 and inhibits T cell activation, Nat. Immunol., 2, 261, 10.1038/85330

Francisco, 2009, PD-L1 regulates the development, maintenance, and function of induced regulatory T cells, J. Exp. Med., 206, 3015, 10.1084/jem.20090847

Blank, 2004, PD-L1/B7H-1 inhibits the effector phase of tumor rejection by T cell receptor (TCR) transgenic CD8+ T cells, Cancer Res., 64, 1140, 10.1158/0008-5472.CAN-03-3259

Iwai, 2003, PD-1 inhibits antiviral immunity at the effector phase in the liver, J. Exp. Med., 198, 39, 10.1084/jem.20022235

Barber, 2006, Restoring function in exhausted CD8 T cells during chronic viral infection, Nature, 439, 682, 10.1038/nature04444

Ahmadzadeh, 2009, Tumor antigen-specific CD8 T cells infiltrating the tumor express high levels of PD-1 and are functionally impaired, Blood, 114, 1537, 10.1182/blood-2008-12-195792

Dong, 2002, Tumor-associated B7-H1 promotes T-cell apoptosis: a potential mechanism of immune evasion, Nat. Med., 8, 793, 10.1038/nm730

Weber, 2015, Nivolumab versus chemotherapy in patients with advanced melanoma who progressed after anti-CTLA-4 treatment (CheckMate 037): a randomised, controlled, open-label, phase 3 trial, Lancet Oncol., 16, 375, 10.1016/S1470-2045(15)70076-8

Robert, 2015, Nivolumab in previously untreated melanoma without BRAF mutation, N. Engl. J. Med., 372, 320, 10.1056/NEJMoa1412082

Weber, 2017, CheckMate 238 collaborators, adjuvant nivolumab versus ipilimumab in resected stage III or IV melanoma, N. Engl. J. Med., 377, 1824, 10.1056/NEJMoa1709030

Brahmer, 2015, Nivolumab versus docetaxel in advanced squamous-cell non–small-cell lung cancer, N. Engl. J. Med., 373, 123, 10.1056/NEJMoa1504627

Borghaei, 2015, Nivolumab versus docetaxel in advanced nonsquamous non–small-cell lung cancer, N. Engl. J. Med., 373, 1627, 10.1056/NEJMoa1507643

Motzer, 2015, Nivolumab versus everolimus in advanced renal-cell carcinoma, N. Engl. J. Med., 373, 1803, 10.1056/NEJMoa1510665

Ferris, 2016, Nivolumab for recurrent squamous-cell carcinoma of the head and neck, N. Engl. J. Med., 375, 1856, 10.1056/NEJMoa1602252

El-Khoueiry, 2017, Nivolumab in patients with advanced hepatocellular carcinoma (CheckMate 040): an open-label, non-comparative, phase 1/2 dose escalation and expansion trial, Lancet, 389, 2492, 10.1016/S0140-6736(17)31046-2

Overman, 2017, Nivolumab in patients with metastatic DNA mismatch repair-deficient or microsatellite instability-high colorectal cancer (CheckMate 142): an open-label, multicentre, phase 2 study, Lancet Oncol., 18, 1182, 10.1016/S1470-2045(17)30422-9

Ansell, 2015, PD-1 blockade with nivolumab in relapsed or refractory Hodgkin's lymphoma, N. Engl. J. Med., 372, 311, 10.1056/NEJMoa1411087

Robert, 2015, Pembrolizumab versus ipilimumab in advanced melanoma, N. Engl. J. Med., 372, 2521, 10.1056/NEJMoa1503093

Schachter, 2017, Pembrolizumab versus ipilimumab for advanced melanoma: final overall survival results of a multicentre, randomised, open-label phase 3 study (KEYNOTE-006), Lancet, 390, 1853, 10.1016/S0140-6736(17)31601-X

Reck, 2016, Pembrolizumab versus chemotherapy for PD-L1–positive non–small-cell lung cancer, N. Engl. J. Med., 375, 1823, 10.1056/NEJMoa1606774

Chen, 2017, Phase II study of the efficacy and safety of pembrolizumab for relapsed/refractory classic Hodgkin lymphoma, J. Clin. Oncol., 35, 2125, 10.1200/JCO.2016.72.1316

Chow, 2016, Antitumor activity of pembrolizumab in biomarker-unselected patients with recurrent and/or metastatic head and neck squamous cell carcinoma: results from the phase Ib KEYNOTE-012 expansion cohort, J. Clin. Oncol., 34, 3838, 10.1200/JCO.2016.68.1478

Bellmunt, 2017, Pembrolizumab as second-line therapy for advanced urothelial carcinoma, N. Engl. J. Med., 376, 1015, 10.1056/NEJMoa1613683

Fuchs, 2018, Safety and efficacy of pembrolizumab monotherapy in patients with previously treated advanced gastric and gastroesophageal junction cancer: Phase 2 Clinical KEYNOTE-059 Trial, JAMA Oncol., 4, 10.1001/jamaoncol.2018.0013

Prasad, 2018, Cancer drugs approved based on biomarkers and not tumor type—FDA approval of pembrolizumab for mismatch repair-deficient solid cancers, JAMA Oncol., 4, 157, 10.1001/jamaoncol.2017.4182

Rittmeyer, 2017, Atezolizumab versus docetaxel in patients with previously treated non-small-cell lung cancer (OAK): a phase 3, open-label, multicentre randomised controlled trial, Lancet, 389, 255, 10.1016/S0140-6736(16)32517-X

Patel, 2018, Avelumab in metastatic urothelial carcinoma after platinum failure (JAVELIN Solid Tumor): pooled results from two expansion cohorts of an open-label, phase 1 trial, Lancet Oncol., 19, 51, 10.1016/S1470-2045(17)30900-2

Antonia, 2017, Durvalumab after chemoradiotherapy in stage III non–small-cell lung cancer, N. Engl. J. Med., 377, 1919, 10.1056/NEJMoa1709937

Wolchok, 2017, Overall survival with combined nivolumab and ipilimumab in advanced melanoma, N. Engl. J. Med., 377, 1345, 10.1056/NEJMoa1709684

Motzer, 2018, Nivolumab plus ipilimumab versus sunitinib in advanced renal-cell carcinoma, N. Engl. J. Med., 378, 1277, 10.1056/NEJMoa1712126

Long, 2017, Standard-dose pembrolizumab in combination with reduced-dose ipilimumab for patients with advanced melanoma (KEYNOTE-029): an open-label, phase 1b trial, Lancet Oncol., 18, 1202, 10.1016/S1470-2045(17)30428-X

Antonia, 2016, Safety and antitumour activity of durvalumab plus tremelimumab in non-small cell lung cancer: a multicentre, phase 1b study, Lancet Oncol., 17, 299, 10.1016/S1470-2045(15)00544-6

Kumar, 2017, Current diagnosis and management of immune related adverse events (irAEs) induced by immune checkpoint inhibitor therapy, Front. Pharmacol., 8, 49, 10.3389/fphar.2017.00049

Larkin, 2015, Combined nivolumab and ipilimumab or monotherapy in untreated melanoma, N. Engl. J. Med., 373, 23, 10.1056/NEJMoa1504030

Nishijima, 2017, Safety and tolerability of PD-1/PD-L1 inhibitors compared with chemotherapy in patients with advanced cancer: a meta-analysis, Oncologist, 22, 470, 10.1634/theoncologist.2016-0419

Man, 2018, Treatment-related toxicities of immune checkpoint inhibitors in advanced cancers: a meta-analysis, Asia Pac. J. Clin. Oncol., 10.1111/ajco.12838

Pitt, 2016, Resistance mechanisms to immune-checkpoint blockade in cancer: tumor-intrinsic and -extrinsic factors, Immunity, 44, 1255, 10.1016/j.immuni.2016.06.001

Kvistborg, 2014, Anti-CTLA-4 therapy broadens the melanoma-reactive CD8+ T cell response, Sci. Transl. Med., 6, 10.1126/scitranslmed.3008918

Ayers, 2017, IFN-γ–related mRNA profile predicts clinical response to PD-1 blockade, J. Clin. Invest., 127, 2930, 10.1172/JCI91190

Tumeh, 2014, PD-1 blockade induces responses by inhibiting adaptive immune resistance, Nature, 515, 568, 10.1038/nature13954

Hargadon, 2017, Strategies to improve the efficacy of dendritic cell-based immunotherapy for melanoma, Front. Immunol., 8, 1594, 10.3389/fimmu.2017.01594

Daud, 2016, Tumor immune profiling predicts response to anti–PD-1 therapy in human melanoma, J. Clin. Invest., 126, 3447, 10.1172/JCI87324

Topalian, 2012, Safety, activity, and immune correlates of anti–PD-1 antibody in cancer, N. Engl. J. Med., 366, 2443, 10.1056/NEJMoa1200690

Rizvi, 2015, Mutational landscape determines sensitivity to PD-1 blockade in non-small cell lung cancer, Science, 348, 124, 10.1126/science.aaa1348

McGranahan, 2016, Clonal neoantigens elicit T cell immunoreactivity and sensitivity to immune checkpoint blockade, Science, 351, 1463, 10.1126/science.aaf1490

Routy, 2018, Gut microbiome influences efficacy of PD-1–based immunotherapy against epithelial tumors, Science, 359, 91, 10.1126/science.aan3706

Ahn, 2016, Demethylation of the PD-1 promoter is imprinted during the effector phase of CD8 T cell exhaustion, J. Virol., 90, 8934, 10.1128/JVI.00798-16

Pauken, 2016, Epigenetic stability of exhausted T cells limits durability of reinvigoration by PD-1 blockade, Science, 354, 1160, 10.1126/science.aaf2807

Blackburn, 2008, Selective expansion of a subset of exhausted CD8 T cells by PD-L1 blockade, Proc. Natl. Acad. Sci., 105, 15016, 10.1073/pnas.0801497105

Chen, 2016, Analysis of immune signatures in longitudinal tumor samples yields insight into biomarkers of response and mechanisms of resistance to immune checkpoint blockade, Cancer Discov., 6, 827, 10.1158/2159-8290.CD-15-1545

Zaretsky, 2016, Mutations associated with acquired resistance to PD-1 blockade in melanoma, N. Engl. J. Med., 375, 819, 10.1056/NEJMoa1604958

Hargadon, 2016, Dysregulation of TGFβ1 activity in cancer and its influence on the quality of anti-tumor immunity, J. Clin. Med., 5, E76, 10.3390/jcm5090076

Torphy, 2017, Newly emerging immune checkpoints: promises for future cancer therapy, Int. J. Mol. Sci., 18, E2642, 10.3390/ijms18122642